Registry Study of Revcovi Treatment in Patients With ADA-SCID
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03878069|
Recruitment Status : Recruiting
First Posted : March 18, 2019
Last Update Posted : December 22, 2020
|Condition or disease||Intervention/treatment|
|Adenosine Deaminase Deficiency Severe Combined Immunodeficiency||Biological: elapegademase-lvlr|
Patients with ADA-SCID who require treatment with Revcovi as Enzyme Replacement Therapy (ERT) will be enrolled during a 24-month period and each will be followed for 24 months after starting Revcovi or until undergoing hematopoietic stem cell transplant (HSCT) or hematopoietic stem cell gene therapy (HSC-GT), whichever occurs first. Patients undergoing HSCT or HSC-GT will be followed one month after last Revcovi dose and again at six months to assess adverse events (AEs) and survival. Throughout the duration of the study, patients will be assessed continually for AEs.
Patients/Parents/Caregivers will self-administer weekly intramuscular (IM) dose(s) of Revcovi and will be followed according to the Suggested Schedule of Assessments for trough dAXP and ADA activity. Treatment dosing and monitoring will be individualized per provider and patient characteristics in adherence with each study sites' standards of care.
Participants in the STP-2279-002 trial will be given the opportunity to enroll in this registry study and proceed to the Treatment Month 6 Visit per the Suggested Schedule of Assessments for Adagen-Transitioning Patients.
An interim analysis will be performed approximately two years after study initiation.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||20 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy|
|Actual Study Start Date :||June 25, 2019|
|Estimated Primary Completion Date :||June 2023|
|Estimated Study Completion Date :||July 2023|
ERT with ADA
Patients with diagnosis of ADA-SCID treated with ERT with Revcovi or transitioning to Revcovi from Adagen
Patients transitioning from Adagen: For patients currently receiving Adagen at ≤ 30 U/kg/wk or an unknown Adagen dose, the suggested dosage of Revcovi is 0.2 mg/kg/wk IM. For patients currently receiving Adagen at > 30 U/kg/wk the suggested equivalent Revcovi dosage (mg/kg/wk) is the Adagen dosage in U/kg/wk divided by 150.
At the investigator's discretion, the total weekly dose may be divided and administered in multiple IM injections, increased by 0.033 mg/kg/wk if trough ADA activity is < 30 mmol/hr/L, dAXP is > 0.02 mmol/L, and/or the immune reconstitution is inadequate.
Adagen-naïve patients: The suggested starting Revcovi dosage is 0.2 mg/kg twice weekly IM based on ideal body weight, for a minimum of 12 to 24 weeks until immune reconstitution is achieved. At the investigator's discretion, the dosage may be gradually increased to maintain trough ADA activity > 30 mmol/hr/L, dAXP < 0.02 mmol/L, and/or to maintain adequate immune reconstitution.
Other Name: Revcovi
- Deoxyadenosine nucleotides (dAXP) activity [ Time Frame: Month 24 ]Total trough erythrocyte dAXP activity
- ADA activity [ Time Frame: Month 24 ]Trough plasma ADA activity
- Immune status (SSA/PI) [ Time Frame: Month 24 ]
Absolute lymphocyte count and subset B, T, and NK analysis.
Immunoglobulin (Ig) concentrations (IgG, IgA, and IgM).
Measurement of immune response at Investigator discretion.
- Clinical status [ Time Frame: Month 24 ]Infections (clinically or microbiologically documented) Incidence and duration of hospitalizations Growth for patients < 18 years old Overall survival through the end of study
- Safety assessed by determining adverse events (AEs), serious adverse events (SAEs) [ Time Frame: Month 24 ]Assessed by determining adverse events (AEs), serious adverse events (SAEs), clinical signs and symptoms from physical examinations, and laboratory examinations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03878069
|Contact: Joseph M Wiley, MD||301-670-2182||Joseph.Wiley@leadiant.com|
|Contact: Elizabeth Walsh||301-670-5447||Elizabeth.Walsh@leadiant.com|
|United States, California|
|University of California Los Angeles||Not yet recruiting|
|Los Angeles, California, United States, 90095|
|Contact: Manish Butte, MD, PhD 310-825-6481|
|Principal Investigator: Manish Butte, MD, PhD|
|United States, Florida|
|University of South Florida Allergy Immunology Clinic||Recruiting|
|Saint Petersburg, Florida, United States, 33701|
|Contact: Jolan Walter, MD, PhD 727-553-1258 firstname.lastname@example.org|
|Contact: Maryssa Ellison email@example.com|
|United States, New York|
|UBMD Pediatrics Outpatient Center||Recruiting|
|Buffalo, New York, United States, 14203|
|Contact: Heather Lehman, MD 716-323-0130 firstname.lastname@example.org|
|Contact: Helena McClenahan email@example.com|
|United States, Pennsylvania|
|UPMC Children's Hospital of Pittsburgh||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15224|
|Contact: Hey Chong, MD 412-692-7785 firstname.lastname@example.org|
|Principal Investigator: Hey Chong, MD|
|United States, Tennessee|
|Le Bonheur Children's Hospital||Recruiting|
|Memphis, Tennessee, United States, 38105|
|Contact: Jay Lieberman, MD 901-287-7337 email@example.com|
|Principal Investigator: Jay Lieberman, MD|
|Study Director:||Joseph M Wiley, MD||Leadiant Biosciences, Inc.|